Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15445381 | 0.83 | SGMS2 (0.31) | ESR1SGMS2 | |
| SCHEMBL2610141 | 0.81 | ALDH1A1 (0.43) | TSHRALDH1A1LMNAMAPTSGMS2 | |
| SCHEMBL3295518 | 0.81 | ALDH1A1 (0.36) | ALDH1A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL30154222 | 0.81 | IDO1 (0.34) | ALDH1A1LMNACYP2C19 | |
| SCHEMBL11042257 | 0.81 | ALDH1A1 (0.42) | TSHRALDH1A1MAPTNPSR1SGMS2 | |
| SCHEMBL18501011 | 0.79 | ESR1 (0.47) | ESR1TSHRALDH1A1MEN1LMNA | |
| SCHEMBL11041678 | 0.79 | GAA (0.35) | ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL9827673 | 0.79 | ALDH1A1 (0.33) | ALDH1A1LMNASGMS2 | |
| SCHEMBL7085423 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MEN1MAPTKMT2AADRA2A | |
| SCHEMBL11043231 | 0.78 | AR (0.37) | SLC6A4ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101885742-B | Chiral diphosphorodiamidate compound and synthesis method thereof | UNIV HEFEI TECHNOLOGY | 2013-01-09 | — | — | CN | disclosed |
| CN-101962391-B | Chiral phosphorus compound | UNIV HEFEI TECHNOLOGY | 2012-09-26 | — | — | CN | disclosed |
| US-8163947-B2 | Cyanation catalyst and method for producing optically active cyanhydrin compound using the same | NATIONAL UNIVERSITY CORPORATION, HOKKAIDO UNIVERSITY (JP) | 2012-04-24 | — | — | US | disclosed |
| CN-101973952-A | Chiral oxazoline and synthetic method thereof | UNIV HEFEI TECHNOLOGY | 2011-02-16 | — | — | CN | disclosed |
| CN-101962391-A | Chiral phosphorus compound | UNIV HEFEI TECHNOLOGY | 2011-02-02 | — | — | CN | disclosed |
| CN-101885742-A | Chiral diphosphorodiamidate compound and synthesis method thereof | UNIV HEFEI TECHNOLOGY | 2010-11-17 | — | — | CN | disclosed |
| US-20100029977-A1 | CYANATION CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYANHYDRIN COMPOUND USING THE SAME | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2010-02-04 | — | — | US | disclosed |
| US-5449682-A | Angiotensin II antagonists incorporating a substituted benzyl element | MERCK & CO., INC. (US) | 1995-09-12 | — | — | US | disclosed |
| US-5240938-A | Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring | MERCK & CO., INC. (US) | 1993-08-31 | — | — | US | disclosed |
| WO-1991011999-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| US-4448971-A | Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1984-05-15 | — | — | US | disclosed |
| US-4407811-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4399296-A | TRIMETHYLSILYL CYANOHYDRIN INTERMEDIATES | PFIZER INC. (US) | 1983-08-16 | — | — | US | disclosed |
| US-4367234-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029977-A1 | CYANATION CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYANHYDRIN COMPOUND USING THE SAME | TYR, IK, CYB5R3 | ESR1 2732/4885TSHR 1007/4885ALDH1A1 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.